Bcl-2 Inhibitor Compounds for Cancer Chemotherapy Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compounds that inhibit the activity of anti-apoptotic Bcl-2 proteins, which are associated with various cancers and immune disorders, as their overexpression leads to chemotherapy resistance and poor clinical outcomes.
Innovation Solution
Development of compounds with specific chemical structures, represented by Formulas I and II, which act as inhibitors of anti-apoptotic Bcl-2 proteins, potentially offering therapeutic benefits by targeting these proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-apoptotic Bcl-2 proteins are overexpressed, then cell survival is enhanced, but chemotherapy resistance and disease progression increase
Solution Approach 1:
The patent converts the harmful effect of Bcl-2 overexpression (chemotherapy resistance) into a beneficial target by designing compounds that specifically inhibit Bcl-2 activity. The invention identifies Bcl-2 as a vulnerability point and creates inhibitors that restore chemotherapy sensitivity while maintaining cell survival in healthy tissues, thereby transforming the harmful overexpression into a treatable condition.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of Bcl-2 interacting molecules. The compounds described in the patent represent specific chemical modifications designed to bind to Bcl-2 and alter its functional parameters, thereby changing its from a protective anti-apoptotic protein into a targeted inhibition object that can be pharmacologically controlled.
2Productivity
If Bcl-2 proteins are inhibited, then chemotherapy sensitivity is improved, but potential toxicity to healthy cells may increase
Solution Approach 1:
The patent applies local quality by creating Bcl-2 specific inhibitors that target the protein's unique structural features. The compounds are designed to interact with specific residues and binding sites of Bcl-2, providing selective inhibition that spares healthy cells from significant toxicity while effectively sensitizing cancer cells to chemotherapy.
Solution Approach 2:
The patent introduces Bcl-2 inhibitors as intermediary substances that mediate between chemotherapy agents and cancer cells. These inhibitors act as bridges that enhance the effectiveness of chemotherapy by preventing Bcl-2 from counteracting the cytotoxic effects, thereby improving overall therapeutic efficacy without directly causing toxicity to healthy tissues.
3Reliability
If existing Bcl-2 inhibitors are used, then anti-apoptotic activity is reduced, but clinical efficacy may be insufficient
Solution Approach 1:
The patent employs composite materials by combining multiple chemical moieties into unified inhibitor compounds. The compounds described integrate various functional groups and structural elements that work synergistically to provide potent Bcl-2 inhibition, thereby achieving both reliable anti-apoptotic activity and improved clinical efficacy through combined molecular functions.
Solution Approach 2:
The patent applies universality by designing Bcl-2 inhibitors that perform multiple functions simultaneously. The compounds are structured to bind to Bcl-2 with high affinity while also facilitating apoptosis, enhancing chemotherapy sensitivity, and potentially modulating other related proteins, thereby achieving multi-functional therapeutic effects that improve overall clinical efficacy.
Data Source
AI summary
Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.